• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB

PATRYS LIMITED - Corporate Spotlight

0.00% ! 0.1¢
Market Cap $2.895M  !

Patrys Limited is focused on the development of its deoxymab platform of cell-penetrating... Patrys Limited is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, both have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown an ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. This allows specific delivery of cancer drugs to multiple types of cancer.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.1¢
Change
0.000(0.00%)
Mkt cap ! $2.895M
Open High Low Value Volume
0.2¢ 0.2¢ 0.1¢ $23.53K 17.28M

Buyers (Bids)

No. Vol. Price($)
55 173743186 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 100525736 32
View Market Depth
Last trade - 15.34pm 04/09/2025 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.